

Based Therapies—Research Tools and Reagents)

4'-and 4',4''-Substituted-3 α -(Diphenylmethoxy)Tropane Analogs as Cocaine Therapeutics

Newman, A.H., Allen, A.C., Kline, R.H., Izenwasser, S., Katz, J.L. (NIDA)

Filed 21 Jun 95

Serial No. 60/000,378

Licensing Contact: Leopold J. Luberecki, Jr., 301/496-7735 ext 223

The invention provides a series of 4'- and 4',4''-substituted benzotropine analogs that demonstrate high affinity binding ($K_i < 30$ nM) to the dopamine transporter and bind selectively (>100-fold) over the other monoamine transporters. These compounds block dopamine reuptake *in vitro* and yet do not demonstrate a cocaine-like behavioral profile in animal models of psychomotor stimulant abuse. Structure-Activity Relationships suggest that these compounds interact at a binding domain that differs from that of cocaine at the dopamine transporter. These compounds represent an unprecedented class of dopamine uptake inhibitors that may have potential as cocaine-abuse therapeutics, since they have neurochemical similarities to cocaine and yet do not appear to have abuse liability. Further, radiolabeled analogs will be suitable for imaging the dopamine transporter in mammalian brain using SPECT and PET and thus would be useful in the diagnoses and monitoring of neurodegenerative disorders involving the dopaminergic system (e.g., Parkinson's disease). In addition, the invention provides pharmaceutical compositions comprising an analog of the invention and a pharmaceutically acceptable carrier excipient. (portfolio: Central Nervous System—Therapeutics, psychotherapeutics, drug dependence; Central Nervous System—Therapeutics, neurological, antiparkinsonian)

Alzheimer's Disease Index (ADI)

Alkon, D.L. (NINDS)

Filed 26 Sep 95

DHHS Reference No. E-092-93/2

Licensing Contact: Stephen Finley, 301/496-7735 ext 215

Under currently available technology, Alzheimer's disease can only be presumptively diagnosed by pathological examination of brain tissue during autopsy in conjunction with a clinical history of dementia. The present invention provides a highly reliable laboratory method of identifying Alzheimer's disease in a patient. The method consists of: measuring the presence or absence of a specific

potassium channel, measuring the effect of potassium channel blockers specific for the 113 pS potassium channel on intracellular calcium levels, measuring the increase of intracellular calcium in response to an activator of intracellular calcium release in the cells of a patient, and measuring the amount of the G-protein, cp20. An index calculated on the basis of any two of these four tests identifies Alzheimer's disease with very high sensitivity and specificity (n=100, initial sample) in comparisons between Alzheimer's disease patients and other non-Alzheimer's dementias as well as age-matched controls. (portfolio: Central Nervous System—Diagnostics, *in vitro*, other).

Dated: February 6, 1996.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 96-3184 Filed 2-12-96; 8:45 am]

BILLING CODE 4140-01-M

National Institute of Allergy and Infectious Diseases; Notice of Meeting: Chronic Fatigue Syndrome Interagency Coordinating Committee; Public Meeting

Notice is hereby given of the public meeting of the Chronic Fatigue Syndrome (CFS) Interagency Coordinating Committee, Department of Health and Human Services, on April 10, 1996 at the William H. Natcher Conference Center, Room E1/2, 45 Center Drive, Bethesda, MD.

The meeting will be open to the public from 1:00 p.m. to 4:00 p.m., on April 10, to discuss the current CFS activities and future plans of the various member agencies. It will be chaired by the Assistant Secretary for Health. During the meeting there will be an opportunity for interested persons to present information and views on issues related to CFS. Attendance by the public will be limited only by space available.

If you plan to attend the meeting, please provide your name, organization, address, telephone and FAX numbers to Dr. John La Montagne, Co-Chair, Chronic Fatigue Syndrome Interagency Coordinating Committee, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Solar Building, Room 3A18 MSC 7630, Bethesda, MD 20892-7630. Telephone: 301-496-1884, FAX: 301-480-4528. If you also plan to make a presentation, please notify Dr. La Montagne. The time available will be allocated among the individuals who request an opportunity for a presentation (limited to five minutes).

Formal written statements (five copies) may be presented to the Chair on the day of the meeting for inclusion in the minutes.

Dated: January 22, 1996.

Anthony S. Fauci,

Director, NIAID, NIH.

[FR Doc. 96-3206 Filed 2-12-96; 8:45 am]

BILLING CODE 4140-01-M

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Allergy and Infectious Diseases Special Emphasis Panel (SEP) meeting:

Name of SEP: National Cooperative Drug Discovery Groups for the Treatment of Opportunistic Infection in AIDS.

Date: March 25-27, 1996.

Time: 8:30 a.m.

Place: Holiday Inn Gaithersburg, 2 Montgomery Village Avenue, Gaithersburg, MD 20879, (301) 948-8900.

Contact Person: Dr. Vassil Georgiev, Scientific Review Adm., 6003 Executive Boulevard, Solar Bldg., Room 4C04, Bethesda, MD 20892-7610, (301) 496-8206.

Purpose/Agenda: To evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Programs Nos. 93.855, Immunology, Allergic and Immunologic Diseases Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health.)

Dated: February 8, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96-3180 Filed 2-12-96; 8:45 am]

BILLING CODE 4140-01-M

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Allergy and Infectious Diseases Special Emphasis Panel (SEP) meeting:

Name of SEP: Clinical Studies of Therapies for Virus Infections.

Date: March 5, 1996.

Time: 11:00 a.m.

Place: Solar Bldg., Room 4C21, 6003 Executive Boulevard, Bethesda, MD 20892.

Contact Person: Dr. Gary S. Madonna, Scientific Review Adm., 6003 Executive Boulevard, Solar Bldg., Room 4C21, Bethesda, MD 20892-7610, (301) 496-3528.

Purpose/Agenda: To evaluate and review a contract proposal.

The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Programs Nos. 93.855, Immunology, Allergic and Immunologic Diseases Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health.)

Dated: February 8, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96-3181 Filed 2-12-96; 8:45 am]

BILLING CODE 4140-01-M

Division of Research Grants; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meeting:

Purpose/Agenda: To review individual grant applications.

Name of SEP: Behavioral and Neurosciences.

Date: February 14-16, 1996.

Time: 8:00 a.m.

Place: Omni Shoreham Hotel, Washington, DC.

Contact Person: Dr. Carole Jelsema, Scientific Review Administrator, 6701 Rockledge Drive, Room 5176, Bethesda, Maryland 20892, (301) 435-1248.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the partial shutdown of the Federal Government and the urgent need to meet timing limitations imposed by the grant review and funding cycle.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: February 8, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96-3166 Filed 2-12-96; 8:45 am]

BILLING CODE 4140-01-M

Division of Research Grants; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

Purpose/Agenda: To review individual grant applications.

Name of SEP: Biological and Physiological Sciences.

Date: February 13, 1996.

Time: 12:00 p.m.

Place: Double Tree Hotel, Rockville, Maryland.

Contact Person: Dr. Sooja Kim, Scientific Review Administrator, 6701 Rockledge Drive, Room 4120, Bethesda, Maryland 20892, (301) 435-1780.

Name of SEP: Biological and Physiological Sciences.

Date: February 13, 1996.

Time: 1:00 p.m.

Place: Double Tree Hotel, Rockville, Maryland.

Contact Person: Dr. Sooja Kim, Scientific Review Administrator, 6701 Rockledge Drive, Room 4120, Bethesda, Maryland 20892, (301) 435-1780.

This notice is being published less than 15 days prior to the above meetings due to the partial shutdown of the Federal Government and the urgent need to meet timing limitations imposed by the grant review and funding cycle.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393, 93.396, 93-837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: February 8, 1996.

Susan K. Feldman,

Committee Management Officer, NIH

[FR Doc. 96-3167 Filed 2-12-96; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[NV-060-1990-01]

Notice of Availability for the Round Mountain Mill and Tailings Facility Final Environmental Impact Statement

AGENCY: Bureau of Land Management, Interior.

ACTION: Notice of availability for the Round Mountain Mill and Tailings Facility final environmental impact statement (EIS), for the Smoky Valley Common Operation, Nye County, Nevada.

SUMMARY: Pursuant to section 102 (2) (C) of the National Environmental Policy Act, 40 CFR 1500-1508, and 43 CFR 3809, notice is given that the Bureau of Land Management (BLM) has prepared and made available a Final EIS on the proposed Round Mountain Mill and Tailings Facility.

DATES: The U.S. Environmental Protection Agency will publish a Notice of Availability for this project in the Federal Register on February 16, 1996. That publication begins the official 30-day availability period for a Final EIS as required by 40 CFR 1506.10.

ADDRESSES: Correspondence may be addressed to: Bureau of Land Management, Battle Mountain District, Post Office Box 1420, Battle Mountain, Nevada 89820, Attn.: Christopher J. Stubbs, Round Mountain EIS Project Manager. A limited number of copies of the Final EIS may be obtained at the same address or by calling Christopher J. Stubbs at (702) 635-4000. In addition, the Final EIS and supporting documentation are available for review at the following locations: BLM, Battle Mountain District Office, Battle Mountain, Nevada; BLM, Nevada State Office, Reno, Nevada; and the Getchell Library, University of Nevada, Reno, Nevada.

FOR FURTHER INFORMATION CONTACT: Christopher J. Stubbs, Round Mountain EIS Project Manager, Bureau of Land Management, Post Office Box 1420, Battle Mountain, Nevada 89820, (702) 635-4000.

SUPPLEMENTARY INFORMATION: The Smoky Valley Common Operation has submitted a Plan of Operations Amendment for the construction, operation, and reclamation of a mill and tailings facility at the Round Mountain Mine. The mine currently consists of 4,767 acres of surface disturbance; 3,659 acres of land administered by the BLM, 515 acres of land administered by the Toiyabe National Forest, and 593 acres